
Tivan signs binding terms by Q3 2026 for up to $50m in stage-gated investment, retaining 82.5% project interest. Sumitomo and ETFS each commit up to $25m.
Tivan (ASX: TVN) has signed term sheets with Sumitomo Corporation and ETFS Capital for up to $50 million in stage-gated investment into the Molyhil tungsten project. The structure leaves Tivan with an effective 82.5% project interest at final investment decision, limiting dilution while bringing in two partners already involved at its Speewah fluorite project.
Sumitomo may invest $25 million for an 8.75% equity stake in the incorporated joint venture. ETFS Capital, the family office of substantial shareholder Graham Tuckwell, would put in another $25 million for an equivalent 8.75% effective interest through Tivan's holding company. Both investments come in two tranches: $4.5 million upfront to fund the pre-feasibility study, then $20.5 million after the DFS and FID.
Sumitomo's memorandum is exclusive and binding in intent. ETFS's is non-binding and non-exclusive. The parties aim to sign long-form agreements by the third quarter of 2026, subject to FIRB approval.
Executive chair Grant Wilson said the framework creates a credible project finance pathway. “We have achieved extreme valuation uplift in a short period of time, whilst ensuring that our strategic partners have strong participation interests,” he said.
Tivan acquired Molyhil in September 2025 after the project sat idle for decades. The resource stands at 4.65 million tonnes grading 0.26% tungsten trioxide and 0.09% molybdenum. An April scoping study returned a base-case NPV of $534 million at an 8% discount rate, an IRR of 114%, and a payback period under one year.
The PFS is due in the fourth quarter of 2026, followed by a DFS and FID. Sumitomo also secured rights to offtake up to 100% of life-of-mine production on commercial terms.
For shareholders, the structure caps partner equity at 17.5% combined, preserving majority upside. The risk is execution: the project still needs a PFS, DFS, and regulatory sign-off. If the studies come in below scoping assumptions, the funding framework may need renegotiation. If they confirm the numbers, Tivan has a funded path to production with minimal further dilution.
Prepared with AlphaScala editorial tooling from the source reporting linked above. Indexable analysis may include a cited Alpha Score value. Publishing checks screen each story before release. Educational coverage, not personalized advice.